Charlotte Pawlyn
机构: Clinician Scientist, The Institute of Cancer Research, London
每年引用次数
引用次数
引用: 4,717
H-指数: 30
I10-指数 : 53
出版物: 163
Multiple myeloma subtyping that associatesnormal B-cell subset phenotypes, do correlate to disease stage and prognosis
Alberto Orfao , Annemiek Broijl , Nikhil Munshi , Martin Bøgsted
15th International Myeloma Workshop
2015
Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial
Mark T Drayson , Charlotte Pawlyn , Walter M Gregory , Martin F Kaiser
Blood 130 436 -436
16
2017
Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide
Mark T Drayson , Andy Rawstron , Ruth M de Tute , Charlotte Pawlyn
Blood 130 904 -904
7
2017
Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial
Amy L Sherborne , Charlotte Pawlyn , Anjan Thakurta , Martin F Kaiser
Blood 130 1851 -1851
2017
Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial
Mark T Drayson , Charlotte Pawlyn , Walter M Gregory , Martin F Kaiser
Blood 130 3040 -3040
2
2017
Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial
Mark T Drayson , Charlotte Pawlyn , Walter M Gregory , Martin F Kaiser
Blood 130 1854 -1854
4
2017
A Systematic Review and Network Meta-Analysis of Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplant
Charlotte Pawlyn , Susanne Schmitz , Sujith Dhanasiri , John Ashcroft
Blood 130 1832 -1832
1
2017
The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide
Mark T Drayson , Amy L Sherborne , Charlotte Pawlyn , Charlotte Pawlyn
Blood 130 396 -396
1
2017
Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models
Charlotte Pawlyn , Charlotte Pawlyn , Rajesh Chopra , Niels Weinhold
Blood 136 6 -7
2020
Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients
Mark T Drayson , Amy L Sherborne , Charlotte Pawlyn , Walter M Gregory
Blood 130 4331 -4331
1
2017
The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients
Charlotte Pawlyn , Walter M Gregory , Faith E Davies , Gareth J. Morgan
Blood 130 3063 -3063
2017
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Mark T. Drayson , Ruth M. de Tute , Charlotte Pawlyn , Charlotte Pawlyn
PLOS Medicine 18 ( 1)
2021
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.
Ramon Garcia-Sanz , Noopur Raje , Charlotte Pawlyn , Evangelos Terpos
Blood Advances 5 ( 3) 725 -736
1
2021
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.
Charlotte Pawlyn , Radovan Saso , Martin Kaiser , Kevin Boyd
The Lancet Haematology 8 ( 6)
126
2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.
Mark Drayson , Charlotte Pawlyn , Charlotte Pawlyn , Walter Gregory
Clinical Lymphoma, Myeloma & Leukemia
2021
Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial
Charlotte Pawlyn , Graham H Jackson , David Cairns , Alina Striha
Blood 132 3280 -3280
2018
Understanding the molecular biology of myeloma and its therapeutic implications.
Kevin D Boyd , Charlotte Pawlyn , Gareth J Morgan , Faith E Davies
Expert Review of Hematology 5 ( 6) 603 -617
14
2012
MM-296: A Real-World Study of Panobinostat, Weekly Bortezomib, and Dexamethasone in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients
Sarah Bird , Charlotte Pawlyn , Susanna Nallamilli , Priya Sriskandarajah
Clinical Lymphoma, Myeloma & Leukemia 20
2020
Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing
Lorenzo Melchor , John R Jones , Oleg Lenive , Erich Allen Peterson
Blood 126 ( 23) 371 -371
4
2015
Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients
Martin F Kaiser , Eileen Mary Boyle , Brian A Walker , Dil B Begum
Blood 126 ( 23) 2983 -2983
2015